BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Gastroenterology and Hepatology - Oncology - Pathology - Surgery

Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
Published: Tuesday, August 14, 2012
Author: Kazushige Ishida et al.

by Kazushige Ishida, Satoshi S. Nishizuka, Takehiro Chiba, Miyuki Ikeda, Kohei Kume, Fumitaka Endo, Hirokatsu Katagiri, Teppei Matsuo, Hironobu Noda, Takeshi Iwaya, Noriyuki Yamada, Hisataka Fujiwara, Masanori Takahashi, Tetsuya Itabashi, Noriyuki Uesugi, Chihaya Maesawa, Gen Tamura, Tamotsu Sugai, Koki Otsuka, Keisuke Koeda, Go Wakabayashi

To confirm the clinical significance of NF-?B and JNK protein expression from experimentally identified candidates for predicting prognosis for patients with 5-FU treatment, we evaluated the protein expression of surgically removed specimens. A total of 79 specimens were obtained from 30 gastric and 49 colorectal cancer patients who underwent R0 resection followed by postoperative 5-FU based adjuvant chemotherapy. Immunohistochemical examinations of NF-?B and JNK on tissue microarrays (TMAs) revealed that significantly shorter time-to-relapse (TTR) in both NF-?B(+) and JNK(-) subgroups in both gastric (NF-?B(+), p?=?0.0002, HR11.7. 95%CI3 3.2–43.4; JNK(-), p?=?0.0302, HR4.4, 95%CI 1.2–16.6) and colon (NF-?B(+), p?=?0.0038, HR36.9, 95%CI 3.2–426.0; JNK(-), p?=?0.0098, HR3.2, 95%CI 1.3–7.7) cancers. These protein expression patterns also show strong discriminately power in gastric cancer patients for overall survival rate, suggesting a potential utility as prognostic or chemosensitivity markers. Baseline expression of these proteins using gastric cancer cell lines demonstrated the reciprocal patterns between NF-?B and JNK, while 5-FU exposure of these cell lines only induced NF-?B, suggesting that NF-?B plays a dominant role in the response to 5-FU. Subsequent siRNA experiments confirmed that gene knockdown of NF-?B increased 5-FU-specific sensitivity, whereas that of JNK did not affect the chemosensitivity. These results suggest that the expression of these proteins may aid in the decisions involved with adjuvant chemotherapy for gastrointestinal tract cancers.
  More...

 

//-->